myelodysplastic syndromes (MDS) | Page 3 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

2022 Memphis Patient and Family Hybrid Conference

Find the recordings for the 2022 Memphis Patient and Family Hybrid Conference here:

Living with PNH

Living with Aplastic Anemia (Adults & Pediatric)

Predisposition to MDS (Pediatric)

Event Date: 
Sat, 07/23/2022 - 8:30am (EDT)
Conference Event Type: 

Aplastic Anemia, MDS, and PNH Virtual Support Group - 2022 August

Event Date: 
Sat, 08/27/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Share with